Repeat stereotactic radiosurgery for Cushing's disease: outcomes of an international, multicenter study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43916344" target="_blank" >RIV/00216208:11120/18:43916344 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/18:N0000027 RIV/00023884:_____/18:00007851

Result on the web

<a href="https://doi.org/10.1007/s11060-018-2817-5" target="_blank" >https://doi.org/10.1007/s11060-018-2817-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11060-018-2817-5" target="_blank" >10.1007/s11060-018-2817-5</a>

Result language

angličtina

Original language name

Repeat stereotactic radiosurgery for Cushing's disease: outcomes of an international, multicenter study

Original language description

Stereotactic radiosurgery (SRS) is frequently used for Cushing&apos;s disease (CD) after failed pituitary surgery. Management of patients with persistent CD after failed SRS is complex, as the alternative therapeutic options harbor significant risks. The outcomes of repeat pituitary radiosurgery, however, have not been described. We sought to determine the outcomes of repeat SRS in patients with CD. We pooled data from five institutions participating in the International Gamma Knife Research Foundation for patients with recurrent or persistent CD GREATER-THAN OR EQUAL TO 12 months after initial SRS. Patients were included in the study if they had GREATER-THAN OR EQUAL TO 6 months endocrine follow-up after repeat SRS. Twenty patients were included in the study. Repeat single-session SRS was performed 1.3-9.7 years after initial SRS. Median endocrine follow-up was 6.6 years (1.4-19.1 years). Median margin dose was 20 Gy (range 10.8-35 Gy). Endocrine remission after second SRS was noted in 12 patients (60%), with a median time to remission of 6 months (range 2-64 months). Biochemical recurrence occurred in two patients (17%) after initial remission. Overall, the cumulative rates of durable endocrine remission at 5 and 10 years were 47 and 53%, respectively. Two patients (10%) experienced adverse radiation effects, including transient visual loss and permanent diplopia. Repeat SRS achieves lasting biochemical remission in approximately half of patients with CD refractory to both prior microsurgery and SRS. Because of the morbidity of refractory or recurrent CD, repeat SRS should be considered for carefully selected patients with hypercortisolism confirmed one or more years after initial SRS.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Neuro-Oncology

ISSN

0167-594X

e-ISSN

—

Volume of the periodical

138

Issue of the periodical within the volume

3

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

519-525

UT code for WoS article

000435363100008

EID of the result in the Scopus database

2-s2.0-85048547274